Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN
Completed · Phase 1 · Has a placebo group
Conditions studied: Painful Diabetic Neuropathy
In brief
A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.
Key facts
- Study ID
- NCT04857957
- Run by
- Centrexion Therapeutics
- People needed
- 46
- Starts
- 2021-04-14
- Expected to finish
- 2023-08-30
- Last updated by the study team
- 2025-07-28
Who can join
Age: 18 and older, up to 59. Sex: any. Healthy volunteers: accepted.
Where it is running
- AltaSciences — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.